picture: ©Boehmert & Boehmert

IP – In a recent decision (Royalty vs. DPMA; C-650/17), the European Court of Justice (ECJ) has shed some light on the conditions under which a supplementary protection certificate (SPC) may be granted. It has thus ended discussions that had arisen following earlier somewhat elusive ECJ-decisions. Whether this will be the last word to be heard on the topic remains to be seen.

Minaris expands the existing production site of former Apceth GmbH near Munich. © Minaris

Japanese CDMO Minaris Regenerative Medicine Co. Ltd  will invest US$64.5m to expand its facilities in Europe and Asia.

© The Protein Brewery BV

Lead investor Novo Growth has led a €22m Series A investment in The Protein Brewery, a Dutch company that is to supplement the market for protein alternatives by fungal protein.

ebm_Guide2020_kl.jpg

Growing sector – growing guide: The 22nd edition of the Guide to German Biotech Companies has been published. Almost 120 companies from the vibrant biotech sector present themselves in the English-language yearbook.

© NASDAQ/Galecto

HBM portfolio company Galecto has raised US$85m through the placement of 5.67 million new shares at a price of US$15 per share at Nasdaq.
 

In March 2021, Dr Jane Robertson will take over the position of Chief Medical Officer at Redx Pharma Plc in Alderley Park.

© NIAID

Boehringer Ingelheim announced the start of Phase II studies of its oral TRPC6 blocker code-named BI 764198 in patients hospitalised for COVID-19.

© CANDOR Bioscience GmbH

AP-Protector® is a long-term stabilizer for alkaline phosphatase (AP) coupled to antibodies or Neutravidin/Streptavidin.

3P Biopharmaceuticals expanded its manufacturing and process development capacities in 2017 launching a new manufacturing site in Noain that even allows commercial production of biologics and cell therapies.

British SpyBiotech has outsourced GMP manufacturing of its VLP vaccine platform to Navarra-based 3P Biopharmaceuticals.

Antibody manufacturing at Bioinvent. © Bioinvent AB

Swedish BioInvent AB has licensed its anti-Fc?RllB antibody BI-1206 for $95m to CASI Pharmaceuticals for distribtion in the Greater China region